

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 (no persons are required to respond to a collection of information unless it contains a valid OMB control number).

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/081.119
		Filing Date	February 21, 2002
		First Named Inventor	Reinhard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 1	of 1	Attorney Docket Number	2300-16932

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials [*]	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Tv		CAHILL, et al. "Characterization of MAD2B and other mitotic spindle checkpoint genes", <i>Genomics</i> , (1999) Vol. 58(2): 181-187.	
		GENBANK Accession No. M86699	
		HANAHAN, et al. "The hallmarks of cancer", <i>Cell</i> , (2000) Vol. 100: 57-70.	
		HARUKI, et al. "Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in human lung cancers", <i>Cancer Letters</i> , (2001) Vol. 162: 201-205.	
		HOGG, et al. "Cell cycle dependent regulation of the protein kinase TTK", <i>Oncogene</i> , (1994) Vol. 9: 89-96.	
		MILLS, et al. "Expression of TTK, a novel human protein kinase, is associated with cell proliferation", <i>J. Biol. Chem.</i> , (1992) Vol. 267: 16000-16006.	
		MIMORI, et al. <i>Oncol. Rep.</i> , (2001) Vol. 8: 39-42.	
		OLESEN, et al. "Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3, and TTK in human bladder cancer, screening for mutations and loss of heterozygosity", <i>Carcinogenesis</i> , (2001) Vol. 22(5): 813-815.	
		SAFFERY, et al. "Components of the human spindle checkpoint control mechanism localize specifically to the active centromere on dicentric chromosomes", <i>Hum. Genet.</i> , (2000) Vol. 107: 376-384.	
		SCHMANDT, et al. "IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression", <i>J. Immunol.</i> , (1994) Vol. 152: 96-105.	
V		TOMIZAWA, et al. "Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau", <i>FEBS</i> , (2001) Vol. 492: 221-227.	

Examiner Signature		Date Considered	10/20/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (SB)



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>			Complete If Known		
			Application Number	10/081.119	
			Filing Date	February 21, 2002	
			First Named Inventor	Reinhard, et al.	
			Group Art Unit	1645	
			Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	2300-16932

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TV			WO 00/56756		Bancroft et al.	09-28-2000		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
Duplicate from 1st IDS		SCHMANDT, et al. "IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression", J. Immunol., (1994) Vol. 152: 96-105.		

7/10/02

Examiner Signature		Date Considered	10/20/04
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (SB)